NCT02957682已完成4 期
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 2,176
- 试验地点
- 3
- 主要终点
- Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96
研究概览
简要总结
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ age 40 years and ≤ age 85 years
- •Patients with heterozygous familial hypercholesterolemia (heFH) or with non-familial hypercholesterolemia (non-FH) patients at high or very high cardiovascular risk
- •Patients with history of coronary heart disease (CHD) not having adequate control of their hypercholesterolemia with LDL-C ≥70 mg/dL, or all other patients with LDL-C ≥100 mg/dL and be on maximally-tolerated dose of statin (unless they are statin-intolerant)
- •Patients must have successfully completed the Motor Screening Task
- •Patients must be willing and able to comply with clinic visits and study related procedures
- •Patients must provide signed informed consent
排除标准
- •Patients with known Alzheimer's disease or other dementia, schizophrenia, bipolar disorder, severe depression, cognitive impairment, or patients with a sleep disorder requiring daily pharmacological treatment
- •Recent (within 3 months prior to the screening visit) myocardial infarction, unstable angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
- •Certain laboratory findings obtained during the screening visit as defined in the protocol
- •Any condition or situation, including other significant mental or neurological disorders that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's participation in the study
- •Pregnant or breastfeeding women
- •A positive human immunodeficiency virus (HIV) test
- •NOTE: Other protocol defined Inclusion/Exclusion Criteria apply
研究组 & 干预措施
Group 1
Experimental
Praluent Regimen - Administration through subcutaneous injection
干预措施: Praluent (Alirocumab) (Drug)
Group 2
Experimental
Placebo matching Praluent - Administration through subcutaneous injection
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96
时间窗: Week 96
CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.
次要结局
- Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96(Week 96)
- Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs(Up to Week 96)
- Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percent Change From Baseline in Apolipoprotein (Apo) A-1 at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percent Change From Baseline in Triglycerides (TG) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
- Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 70 mg/dL (1.81 Millimoles Per Liter [mmol/L]) at Week 12, 24, 48, 72, and 96(Week 12, 24, 48, 72, and 96)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
早期 1 期
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With DonepezilAlzheimer's DiseaseNCT01024660AstraZeneca155
已完成
2 期
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseCentral Nervous System DiseasesCognitionAlzheimer's DiseaseNCT01073228FORUM Pharmaceuticals Inc409
已完成
2 期
Safety and Cognitive Function Study of EVP-6124 in Patients With SchizophreniaCentral Nervous System DiseasesCognitionSchizophreniaNCT00968851FORUM Pharmaceuticals Inc317
已完成
2 期
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's DiseaseSevere Alzheimer DiseaseNCT03765762Alkahest, Inc.26
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, HypertrophicNon-obstructive Hypertrophic CardiomyopathyNCT06481891Lexicon Pharmaceuticals500